Marinus Pharmaceuticals Inc (MRNS)
1.42
-0.14
(-8.97%)
USD |
NASDAQ |
May 08, 16:00
1.44
+0.02
(+1.41%)
After-Hours: 20:00
Marinus Pharmaceuticals Shareholders Equity (Quarterly): 16.76M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 16.76M |
September 30, 2023 | 54.54M |
June 30, 2023 | 57.34M |
March 31, 2023 | 85.08M |
December 31, 2022 | 116.00M |
September 30, 2022 | 82.00M |
June 30, 2022 | 4.803M |
March 31, 2022 | 40.40M |
December 31, 2021 | 53.49M |
September 30, 2021 | 78.49M |
June 30, 2021 | 95.06M |
March 31, 2021 | 115.33M |
December 31, 2020 | 137.20M |
September 30, 2020 | 87.42M |
June 30, 2020 | 101.14M |
March 31, 2020 | 71.31M |
December 31, 2019 | 87.77M |
September 30, 2019 | 34.07M |
June 30, 2019 | 46.58M |
March 31, 2019 | 57.74M |
December 31, 2018 | 68.32M |
Date | Value |
---|---|
September 30, 2018 | 35.12M |
June 30, 2018 | 45.02M |
March 31, 2018 | 53.12M |
December 31, 2017 | 58.01M |
September 30, 2017 | 62.10M |
June 30, 2017 | 16.29M |
March 31, 2017 | 19.25M |
December 31, 2016 | 21.48M |
September 30, 2016 | 26.69M |
June 30, 2016 | 32.33M |
March 31, 2016 | 40.57M |
December 31, 2015 | 46.92M |
September 30, 2015 | 25.66M |
June 30, 2015 | 29.88M |
March 31, 2015 | 34.73M |
December 31, 2014 | 41.15M |
September 30, 2014 | 44.23M |
June 30, 2014 | 4.476M |
March 31, 2014 | 8.538M |
December 31, 2013 | 9.458M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
4.803M
Minimum
Jun 2022
137.20M
Maximum
Dec 2020
71.83M
Average
78.49M
Median
Sep 2021
Shareholders Equity (Quarterly) Benchmarks
Ligand Pharmaceuticals Inc | 700.91M |
Soligenix Inc | 2.522M |
Actinium Pharmaceuticals Inc | 43.86M |
Macrogenics Inc | 152.61M |
ADMA Biologics Inc | 135.21M |
Shareholders Equity (Quarterly) Related Metrics
Total Assets (Quarterly) | 170.91M |
Total Liabilities (Quarterly) | 154.14M |
Debt to Equity Ratio | 4.353 |
Current Ratio | 4.068 |
Net Debt Paydown Yield | -0.07% |